Drugs / CM518D1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07019779 | Jun 2025 → Dec 2028 expected | cancer | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | Keymed Biosciences Co.Ltd | Regulatory 康诺亚CDH17 ADC药物CM518D1开展I/II期临床研究，瞄准实体瘤治疗新靶点 keymedbio.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | Keymed Biosciences Co.Ltd | 康诺亚CDH17 ADC药物CM518D1开展I/II期临床研究，瞄准实体瘤治疗新靶点 keymedbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM518D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07019779 ↗ |
| Route | Intravenous | “administered intravenously” NCT07019779 ↗ |